Molecular and immune heterogeneity across limited-stage and extensive-stage small cell lung cancer
Small-cell lung cancer (SCLC) is a highly aggressive form of lung cancer with poor prognosis. This study explores the molecular differences between limited-stage (LS) and extensive-stage (ES) SCLC using transcriptomic profiling of a large patient cohort.